reported a more favorable prognosis for the KMT2A :: MLLT3 subgroup, with 5-year OS of 28%, although this difference did not reach statistical significance [ 26 ].
← all excerpts
Impact of Fusion Partners and Transplantation Benefit in Intensively Treated <i>KMT2A</i>-Rearranged Acute Myeloid Leukemia.
1
—
—